Lifestyle
- Regular aerobic exercise
- Weight management
- Smoking cessation
Low-Density Lipoprotein · LDL-C · LDL
LDL-C quantifies the cholesterol content within low-density lipoproteins in the bloodstream.
Fasting is recommended for accurate measurement. Reference ranges may vary slightly by laboratory.
Low-Density Lipoprotein Cholesterol (LDL-C) is a type of lipoprotein that transports cholesterol in the blood. It is often referred to as 'bad cholesterol' because high levels can lead to plaque buildup in arteries and result in cardiovascular diseases. Biologically, LDL-C measures the cholesterol content within low-density lipoproteins, which are responsible for delivering cholesterol to cells throughout the body. Clinically, LDL-C is a critical marker for assessing the risk of atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease, peripheral vascular disease, and cerebrovascular disease. Elevated LDL-C levels are strongly associated with an increased risk of major adverse cardiovascular events (MACEs), as demonstrated in large cohort studies. In the context of athletic performance and biohacking, maintaining optimal LDL-C levels is essential for cardiovascular health, which can indirectly affect endurance and recovery. Some biohackers aim to optimize lipid profiles to enhance longevity and reduce inflammation. However, LDL-C levels can be influenced by various factors, including genetic predispositions, dietary habits, and the presence of other lipid disorders. It is important to consider potential confounders such as lipoprotein(a) levels, which can interfere with LDL-C measurements. Fasting is typically required for accurate assessment, and time-of-day variations are minimal. Researchers emphasize the importance of considering LDL-C alongside other markers like high-sensitivity C-reactive protein (Hs-CRP) and triglycerides for a comprehensive cardiovascular risk assessment.
Klinische Bedeutung
Elevated LDL-C levels indicate an increased risk of atherosclerotic cardiovascular diseases, including heart attacks and strokes. Reduced levels are generally favorable and associated with a lower risk of cardiovascular events.
Progressively rising LDL-C levels suggest worsening lipid profile and increased cardiovascular risk. Retesting is recommended every 3-6 months if levels are above optimal range.
Progressively falling LDL-C levels generally indicate improved cardiovascular health and reduced risk of atherosclerosis.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any supplementation, especially if taking statins or other medications.
Testing Frequency
Annually for healthy adults, more frequently if at risk for cardiovascular disease.
Correlated with
Current research suggests that the optimal targets for LDL-C levels and the impact of confounders such as lipoprotein(a) on cardiovascular risk remain debated, particularly in patients on cholesterol-lowering medications. Researchers have not yet established standardized reference ranges for LDL-C corrected for Lp(a) content. Additionally, clinical questions remain unanswered regarding the long-term effects of emerging therapies like pelacarsen on cardiovascular outcomes and the interplay between LDL-C and other inflammatory markers in predicting major adverse cardiovascular events.
917
Total Citations
11
Human/RCT
6.0
Avg. Influence
2025
Latest
This review discussed the triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) ratio as a risk marker for metabolic syndrome and cardiovascular disease. Researchers found that low-density lipoprotein cholesterol (LDL-C) is a major contributor to atherosclerosis, and the TG/HDL-C ratio may help predict the risk of cardiovascular disease. The study highlights the importance of lipid metabolism in cardiovascular health.
This review examined the significance of apolipoprotein B (apoB) as a biomarker for cardiovascular disease. Researchers found that apoB levels provide a more accurate measure of atherogenic lipoproteins compared to low-density lipoprotein cholesterol (LDL-C). The review discusses the ongoing debate regarding the use of apoB in clinical guidelines for cardiovascular risk assessment.
This systematic review and meta-analysis evaluated blood-derived proteins as potential biomarkers for post-stroke cognitive impairment (PSCI). Researchers found that levels of low-density lipoprotein cholesterol (LDL-C) were significantly higher in patients with PSCI compared to those without. The study suggests LDL-C, along with other biomarkers, may be useful in identifying patients at risk for cognitive impairment following a stroke.
This study explored the role of second-generation obesity medications in treating obesity as a chronic disease. Researchers found that these medications can achieve significant weight loss, which may help manage complications associated with obesity. The study emphasizes the importance of using weight loss as a biomarker to improve health outcomes in patients with obesity.
This study investigated the relationship between low-density lipoprotein cholesterol (LDL-C) levels and bone mineral density (BMD) in adults aged 20 to 59. Researchers found a negative association between LDL-C and lumbar BMD, indicating that higher LDL-C levels may be linked to lower bone density. The study suggests that LDL-C could serve as a biomarker for early osteoporosis detection.
This narrative review examined the relationship between hypothyroidism and lipid abnormalities, particularly low-density lipoprotein cholesterol (LDL-C). Researchers found that elevated thyroid-stimulating hormone (TSH) levels are associated with increased LDL-C levels. The study suggests that treating hypothyroidism may reverse lipid abnormalities and improve cardiovascular health.
This study examined the effect of pelacarsen on low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) cholesterol (Lp(a)-C) in patients with cardiovascular disease. Researchers found that pelacarsen significantly reduced Lp(a)-C levels and had neutral to mild effects on corrected LDL-C levels. The study suggests that corrected LDL-C provides a more accurate reflection of changes in LDL-C than laboratory-reported values.
This review highlighted the clinical significance of electronegative low-density lipoprotein (L5 LDL) cholesterol in atherothrombosis. Researchers found that elevated L5 LDL levels correlate with the severity of cardiovascular diseases. The study proposes that L5 LDL could be a promising biomarker for assessing cardiovascular risk and guiding treatment decisions.
This review focused on recombinant high-density lipoprotein formulations as potential therapies for cardiovascular disease. Researchers noted that low-density lipoprotein cholesterol (LDL-C) lowering therapies have limited effectiveness in raising HDL-C levels. The study emphasizes the need for further clinical trials to evaluate the efficacy of novel HDL-modifying therapies.
This article focused on lipoprotein(a) as an independent risk factor for cardiovascular disease (CVD). Researchers found that elevated lipoprotein(a) levels contribute to residual CVD risk even after LDL-C lowering. The study calls for targeted strategies to reduce lipoprotein(a) levels in at-risk patients.
Research publications about LDL-Cholesterin over time
7totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer